USFDA inspection of Shilpa Medicare Unit VI at Bengaluru
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
Akums Drugs will undertake this development and commercialization in India
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Subscribe To Our Newsletter & Stay Updated